HLA SUBTYPING IN ANTIBODY MEDIATED LIMBIC ENCEPHALITIS

Completed

• Conditions: brain inflammation; 10007951; 10003816; Limbic encephalitis

• Registration Number: NL-OMON42370
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 41

Inclusion Criteria

- Limbic encephalitis due to antibodies to LGI1, Caspr2, NMDAR, GABA-B or GAD65, recently or in the past
- Current age > 18 years
- Caucasoid race

Exclusion Criteria

- Not mentally competent to give informed consent
- Patient is withholding informed consent, or objects after initial consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The frequency of HLA-A, B, C, DR and DQ alleles </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>If a specific HLA allele is detected in a subgroup of LGI1 patients, we will<br /><br>analyze whether there are specific patient characteristics or disease<br /><br>characteristics in this subgroup<br /><br><br /><br>Amendement: analyze the relevant LGI1 epitope (fragment of the protein to which<br /><br>inflammatory cells bind) </p><br>